EP4255936A4 - Bcma-targeted chimeric antigen receptors - Google Patents

Bcma-targeted chimeric antigen receptors

Info

Publication number
EP4255936A4
EP4255936A4 EP21901383.6A EP21901383A EP4255936A4 EP 4255936 A4 EP4255936 A4 EP 4255936A4 EP 21901383 A EP21901383 A EP 21901383A EP 4255936 A4 EP4255936 A4 EP 4255936A4
Authority
EP
European Patent Office
Prior art keywords
bcma
chimeric antigen
antigen receptors
targeted chimeric
targeted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21901383.6A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4255936A1 (en
Inventor
Yihong Yao
Jiaqi Huang
Xin Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Abelzeta Ltd
Original Assignee
Shanghai Abelzeta Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/476,661 external-priority patent/US11498973B2/en
Application filed by Shanghai Abelzeta Ltd filed Critical Shanghai Abelzeta Ltd
Publication of EP4255936A1 publication Critical patent/EP4255936A1/en
Publication of EP4255936A4 publication Critical patent/EP4255936A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
EP21901383.6A 2020-12-02 2021-12-01 Bcma-targeted chimeric antigen receptors Pending EP4255936A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063120692P 2020-12-02 2020-12-02
US202163153666P 2021-02-25 2021-02-25
US202163212289P 2021-06-18 2021-06-18
US17/476,661 US11498973B2 (en) 2018-04-12 2021-09-16 BCMA-targeted chimeric antigen receptor as well as preparation method therefor and application thereof
PCT/US2021/061410 WO2022119923A1 (en) 2020-12-02 2021-12-01 Bcma-targeted chimeric antigen receptors

Publications (2)

Publication Number Publication Date
EP4255936A1 EP4255936A1 (en) 2023-10-11
EP4255936A4 true EP4255936A4 (en) 2025-01-22

Family

ID=81853652

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21901383.6A Pending EP4255936A4 (en) 2020-12-02 2021-12-01 Bcma-targeted chimeric antigen receptors

Country Status (7)

Country Link
EP (1) EP4255936A4 (https=)
JP (1) JP2023553390A (https=)
KR (1) KR20230117367A (https=)
CN (1) CN116997345A (https=)
AU (1) AU2021393434A1 (https=)
CA (1) CA3201008A1 (https=)
WO (1) WO2022119923A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250131823A (ko) * 2023-03-31 2025-09-03 아벨제타 인크. Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체
KR102869233B1 (ko) * 2024-01-24 2025-10-15 주식회사 박셀바이오 Bcma 특이적 키메라 항원 수용체를 포함하는 신규한 골수 침윤 림프구 집단 및 이의 제조방법
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
WO2026006767A1 (en) 2024-06-28 2026-01-02 Dispatch Biotherapeutics, Inc. Tethered il-9/il-9r and related engineered cells and methods
CN119119274A (zh) * 2024-09-26 2024-12-13 北京昌盛鸿途生物科技有限公司 一种靶向bcma的cart细胞及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150051266A1 (en) * 2012-04-11 2015-02-19 The USA, as represented by the Secretary, Department of Health and Human Serivces Chimeric antigen receptors targeting b-cell maturation antigen
WO2019196713A1 (zh) * 2018-04-12 2019-10-17 西比曼生物科技（香港）有限公司 靶向bcma的嵌合抗原受体及其制法和应用
WO2020025596A1 (en) * 2018-07-31 2020-02-06 Amgen Research (Munich) Gmbh Dosing regimen for bcma-cd3 bispecific antibodies
US20200261501A1 (en) * 2016-11-04 2020-08-20 Bluebird Bio, Inc. Anti-bcma car t cell compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7599205B2 (ja) * 2018-06-01 2024-12-13 アンヘレス セラピューティクス インコーポレイテッド 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150051266A1 (en) * 2012-04-11 2015-02-19 The USA, as represented by the Secretary, Department of Health and Human Serivces Chimeric antigen receptors targeting b-cell maturation antigen
US20200261501A1 (en) * 2016-11-04 2020-08-20 Bluebird Bio, Inc. Anti-bcma car t cell compositions
WO2019196713A1 (zh) * 2018-04-12 2019-10-17 西比曼生物科技（香港）有限公司 靶向bcma的嵌合抗原受体及其制法和应用
WO2020025596A1 (en) * 2018-07-31 2020-02-06 Amgen Research (Munich) Gmbh Dosing regimen for bcma-cd3 bispecific antibodies

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BERAHOVICH ROBERT ET AL: "CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth", CANCERS, MDPI AG, CH, vol. 10, no. 9, 11 September 2018 (2018-09-11), XP002790575, ISSN: 2072-6694, DOI: 10.3390/CANCERS10090323 *
BERNABEI LUCA ET AL: "PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 132, 29 November 2018 (2018-11-29), pages 1973, XP086590769, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2018-99-119514 *
FENG DEMING ET AL: "Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 92, no. 2, 17 June 2020 (2020-06-17), GB, pages 109 - 119, XP055881933, ISSN: 0300-9475, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1111/sji.12910> DOI: 10.1111/sji.12910 *
METELO ANA M ET AL: "Allogeneic Anti-Bcma CAR-T Cells Show Tumour Specific Killing Against Primary Multiple Myeloma Cells from Different Genomic Sub-Groups", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 134, 13 November 2019 (2019-11-13), pages 1834, XP086671640, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2019-124312 *
See also references of WO2022119923A1 *

Also Published As

Publication number Publication date
CA3201008A1 (en) 2022-06-09
AU2021393434A1 (en) 2023-06-22
JP2023553390A (ja) 2023-12-21
CN116997345A (zh) 2023-11-03
WO2022119923A1 (en) 2022-06-09
EP4255936A1 (en) 2023-10-11
KR20230117367A (ko) 2023-08-08

Similar Documents

Publication Publication Date Title
EP4255936A4 (en) Bcma-targeted chimeric antigen receptors
IL285909A (en) Anti-bcma chimeric antigen receptors
IL279979A (en) Chimeric antigen receptors with bcma specificity and uses thereof
IL280029A (en) Ror-1 specific chimeric antigen receptors and uses thereof
EP3842462A4 (en) BCMA SINGLE-DOMAIN ANTIBODY-BASED CHEMICAL ANTIGEN RECEPTOR AND USE THEREOF
IL280033A (en) Uses of anti-bcma chimeric antigen receptors
IL281428A (en) Chimeric antigen receptor
EP4204457A4 (en) Bcma chimeric antigen receptors
EP3999550A4 (en) ANTI-DLL3 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES
IL259120B (en) Chimeric antigen receptors targeting her2
IL276836A (en) Cd83-binding chimeric antigen receptors
EP3793608A4 (en) COMPOUNDS TARGETING ANTICANCER NUCLEAR HORMONE RECEPTORS
SI3230321T1 (sl) BCMA himerni antigenski receptorji
DK3806903T3 (da) Cd79a kimæriske antigenreceptorer
IL258502A (en) Chimeric antigen receptors targeted to psca
LT3134432T (lt) Mnd promotorius chimerinių antigenų receptoriams
PT3227339T (pt) Recetores de antigénio quiméricos que têm como alvo o recetor 4 acoplado a proteína g e utilizações dos mesmos
EP3762430A4 (en) DIMER ANTIGEN RECEPTORS (DAR)
EP4100428A4 (en) CHIMERIC ANTI-DINITROPHENOL ANTIGEN RECEPTORS
IL289899A (en) Anti-hk2 chimeric antigen receptor (car)
DK3959235T5 (da) Rituximab-resistente kimære antigenreceptorer og anvendelser deraf
EP3604344A4 (en) CHEMICAL ANTIGENIC RECEPTOR
IL307408A (en) Chimeric antigen receptors to target cd5-positive cancers
IL291282A (en) Chimeric cytokine receptors
IL299865A (en) Multispecific chimeric antigen receptors and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230630

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20240322

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SHANGHAI ABELZETA LTD.

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07K0019000000

Ipc: C07K0016280000

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/62 20060101ALI20240925BHEP

Ipc: A61K 35/17 20150101ALI20240925BHEP

Ipc: C07K 19/00 20060101ALI20240925BHEP

Ipc: C07K 16/28 20060101AFI20240925BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20241223

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/62 20060101ALI20241217BHEP

Ipc: A61K 35/17 20150101ALI20241217BHEP

Ipc: C07K 19/00 20060101ALI20241217BHEP

Ipc: C07K 16/28 20060101AFI20241217BHEP